Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
Biomea Fusion, Inc. (BMEA)
Company Research
Source: GlobeNewswire
Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucagon-like peptide-1 (“GLP-1”) based therapiesSuccessfully completed icovamenib food-effect study, establishing optimal dosing conditions to support late-stage clinical studies Successfully completed icovamenib chronic toxicology studies, supporting potential flexibility to evaluate clinical dosing beyond the validated 12-week regimenAdvancing BMF-650 through clinical development as an oral next-generation GLP-1 receptor agonist candidate designed to deliver effective and patient-friendly metabolic benefitsCompany to share 2026 strategy at the 44th Annual J.P. Morgan Healthcare Conference SAN CARLOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today outlined its executi
Show less
Read more
Impact Snapshot
Event Time:
BMEA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMEA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMEA alerts
High impacting Biomea Fusion, Inc. news events
Weekly update
A roundup of the hottest topics
BMEA
News
- Biomea Fusion (NASDAQ:BMEA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
- Biomea Fusion (NASDAQ:BMEA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $12.00 price target on the stock.MarketBeat
- Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Insider Spends US$99k Buying More Shares In Biomea Fusion [Yahoo! Finance]Yahoo! Finance
BMEA
Earnings
- 11/4/25 - Miss
BMEA
Sec Filings
- 1/14/26 - Form 8-K
- 1/6/26 - Form S-8
- 12/15/25 - Form 4
- BMEA's page on the SEC website